Core Insights - Smith+Nephew announces findings from a comparative study on single-use negative pressure wound therapy (sNPWT) devices, highlighting the benefits of PICO sNPWT in reducing surgical complications and healthcare costs [1][2]. Study Findings - The study analyzed data from over 22,000 patients, showing that prophylactic use of PICO sNPWT (-80 mmHg) significantly reduces the risk of wound dehiscence, hospital length of stay (LoS), and overall healthcare costs compared to PrevenaTM (-125 mmHg) sNPWT [2][3]. - Key findings include a 57.8% relative reduction in wound dehiscence risk, a 9.1% relative reduction in LoS (6.33 days vs. 6.86 days), and a 10.34% relative reduction in admission-related costs [5]. Economic Impact - The use of PICO sNPWT resulted in substantial cost savings, with a 21.95% relative reduction in mean index admission cost and a 21% reduction in costs at 30- and 90-day post-surgery [5][6]. - The study indicates that PICO sNPWT may help reduce surgical site complications (SSCs) for at-risk patients, thereby alleviating strain on healthcare resources [6]. Clinical Recommendations - The findings align with global recommendations from organizations such as NICE, WHO, and ACS/SIS, which advocate for the use of incisional negative pressure wound therapy (iNPWT) to minimize the risk of surgical site infections (SSIs) [6][14].